Federal Supply Schedule 36F79720D0213
Award Date
9/15/20
Last Date to Order
9/14/25
Federal Agency
Veterans Integrated Service Network 12
Awardee
Servier Pharmaceuticals LLC
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Fixed Price with Economic Price Adjustment
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
The U.S. Department of Veterans Affairs (VA) awarded a $10 million Blanket Purchase Agreement (BPA) to Servier Pharmaceuticals LLC, a for-profit pharmaceutical company, to provide the specialty oncology medications asparlas and oncaspar over a five-year period. This single-award BPA was issued against Servier's existing Federal Supply Schedule (FSS) contract for pharmaceuticals and drugs. The VA has placed several fixed-price call orders against this BPA for delivery of asparlas and oncaspar...
This Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Servier Pharmaceuticals LLC as a single-award contract with potential value of $12 million. The BPA is for the purchase of the pharmaceutical products Asparlas and Oncaspar, to be delivered over a base year and four option years. The Department of Veterans Affairs provides healthcare services to military veterans. This BPA aims to procure chemotherapy drugs Asparlas and Oncaspar...
This Federal Supply Schedule (FSS) contract awarded by the Department of Veterans Affairs (VA) to Astellas Pharma US, Inc., a foreign-owned pharmaceutical manufacturer, provides for the procurement of drugs and pharmaceuticals, including specialty oncology medications. The $3.5 billion contract, awarded in 2021 with a period of performance through 2026, was established under the Pharmaceuticals and Drugs GSA Schedule (FSS-61-IB) and is designated as a multiple award vehicle. Under this FSS...
The Department of Veterans Affairs (VA) has awarded Ferring Pharmaceuticals Inc., a for-profit pharmaceutical manufacturer, a multiple-award indefinite-delivery vehicle (IDV) contract against the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), valued at $98.2 million over five years. This contract enables Ferring to supply the oncology medication Adstiladrin (nadofaragene firadenovec) to various Veterans Integrated Service Networks (VISNs) across the United States to support the...
The Department of Veterans Affairs (VA) has awarded a Federal Supply Schedule (FSS) contract, V797D70240, to Helsinn Therapeutics (U.S.), Inc. (doing business as Helsinn Therapeutics US Inc.), a for-profit manufacturer of pharmaceutical products. The FSS contract, under the Pharmaceuticals and Drugs (FSS-61-IB) schedule, has a ceiling value of $3,281,482.80 and a period of performance through February 2025. Under this FSS contract, Helsinn Therapeutics has received several delivery order...
The Department of Veterans Affairs (VA) awarded a Federal Supply Schedule (FSS) contract to Blueprint Medicines Corporation, a large business prime contractor, to provide pharmaceutical and hematology-related products under the Pharmaceuticals and Drugs (FSS-61-IB) schedule. The contract has a ceiling value of $3,000,000 and a period of performance through July 31, 2025, allowing the VA to place task orders for drug products as needed. Under this multi-award FSS vehicle, the VA's Veterans...
The U.S. Department of Veterans Affairs (VA) has awarded a multiple award Federal Supply Schedule (FSS-61-IB) contract to Sobi, Inc., a foreign-owned, for-profit pharmaceutical company, with a ceiling value of $78 million through July 2025. This contract enables the VA to procure pharmaceuticals and drug products, such as TEGSEDI and ORFADIN, to support healthcare services for veterans. Additionally, the VA National Acquisition Center has awarded a single-award Blanket Purchase Agreement (BPA)...
The U.S. Department of Veterans Affairs (VA) has awarded a single-award Blanket Purchase Agreement (BPA) to Ferring Pharmaceuticals Inc., a for-profit manufacturer of pharmaceutical goods, under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The $5.96 million BPA, with a period of performance through March 2026, enables the VA to procure the drug Adstiladrin (nadofaragene firadenovec), a treatment for genitourinary cancers, to support the provision of healthcare services to...
The Department of Veterans Affairs (VA) has awarded Incyte Corporation, a global biopharmaceutical company, a $541 million multiple-award Federal Supply Schedule (FSS-61-IB) contract and a $3.75 million single-award Blanket Purchase Agreement (BPA) to provide pharmaceutical products, with a focus on the oncology drug Pemazyre (pemigatinib). The FSS contract covers a range of pharmaceuticals, drugs, and hematology-related products, while the BPA is specifically for the supply of Pemazyre...
The Department of Veterans Affairs (VA) awarded a Federal Supply Schedule (FSS) contract, valued at up to $3.5 million, to Calliditas Therapeutics US Inc., a foreign-owned, for-profit pharmaceutical company. The contract, under the Pharmaceuticals and Drugs (FSS-61-IB) schedule, facilitates the procurement of TARPEYO, an innovative treatment for uncontrolled protein in urine due to primary immunoglobulin A nephropathy, a serious renal condition impacting some veterans. In addition to the FSS...